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P55 ACHROMOBACTER XYLOSOXIDANS: FOLLOW-UP OF 20
PATIENTS WITH CHRONIC INFECTION
D. Costantini1, A. Bifﬁ2, M.L. Garlaschi3, L. Zazzeron1, G. Clarizia3,
C. Colombo1, L. Cariani2. 1CF Centre, Department of Pediatrics, University
of Milan; Fondazione IRCCS, Ospedale Maggiore Policlinico, Mangiagalli
e Regina Elena, Milano; 2CF Centre, Microbiology Laboratory, Fondazione
IRCCS, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano;
3Microbiology Laboratory, Fondazione IRCCS, Ospedale Maggiore Policlinico,
Mangiagalli e Regina Elena, Milano, Italy
Background: A. xylosoxidans (Ax) is capable of persistent infection of the respira-
tory tract of Cystic Fibrosis patients although its contribution to pulmonary decline
in this population is not clear.
Aim: To evaluate pathogenic role of Ax studying lung function and nutritional
status in CF patients with chronic Ax infection.
Methods: Data (FEV1, FVC, BMI, sputum and number of IV therapy) of 20
CF patients in follow-up at our centre were studied retrospectively at the time of
establishment of infection (T0), one year before (T-1) and one year after (T+1) and
were then compared. Statistical analysis was performed by Student’s T test. Mean
age of the 20 (13 females) patients was 14.5 (range 6.2−23.3) at T0.
Results: Lung function showed a slight decrease in the year before the acquisition
of Ax both in FVC (91.2±20.4 vs 86.1±12.6%/predicted p = 0.22) and FEV1
(84.4±20.5 vs 79.1±16.3 %/predicted p = 0.09), without reaching statistical sig-
niﬁcance. Respiratory data showed no deterioration in the year after infection: FVC
(88.4±18.1 vs 86.1±12.6%/predicted p = 0.47) and FEV1 (82.9±23.2 vs 79.1±16.3
%/predicted p = 0.26). However, the number of respiratory exacerbations was much
higher in the year after colonisation as demonstrated by the i.v. treatment mean
days per patient (12.1±15.5 vs 3.1±6.5, p = 0.03).
Nutritional status remained unchanged during the study period as demonstrated by
BMI of T-1 vs T0 (18.1±2.9 vs 18.1±3.1 p = 0.77) and T0 vs T+1 (18.1±3.1 vs
18.7±2.9 p = 0.07).
Conclusion: The pathogenic role of chronic infection by Ax seems to be relevant
in terms of therapeutic burden for patients in the short-term. A key factor would
be monitoring the evolution of the patients chronically infected by Ax.
P56 OXIDATIVE STATUS CHANGE IN CYSTIC FIBROSIS (CF) AND
ORAL ADDITION WITH WHEY PROTEIN ISOLATE WITH HIGH
CONTENT OF CYSTEINE: PRELIMINARY OBSERVATIONS
S. Beschi, L. Minicucci, R. Casciaro, C. Zucchi, M. Haupt, S. Pessano, T. Mora,
A. De Alessandri. Regional Cystic Fibrosis Centre, G. Gaslini Institute, Genoa,
Italy
Oxidative status has a role in the progressive lung damage in CF. Glutathione is
an important defence from pro-antioxidant agents and it is reduced in CF. Cysteine
is the amino acid that gives to glutathione antioxidant status. The objective of this
study is to reduce the oxidative status in CF with oral addition of whey protein
isolate with high content of cysteine (PROther). We recruit CF patients older than
6 years, with a FEV1<70%, with a BMI <21 kg/m2 in adults and with a weight
<25º centile in children. Oxidative status is estimated on a blood sample with
d-ROMs test and BAP test that can measure oxidative stress and antioxidant status
respectively. The study has started in May 2007 and will last for 12 months. Patients
will be checked every three months. We have planed the enrolment of 50 patients
at least. During the follow-up at every examination we will control oxidative status,
clinical conditions (nutritional status, growth, lung function), compliance to the
administration of PROther, alimentary intake and Quality of life. We recruited
32 patients still now. All cases show a pathological condition of oxidative status.
Oxidative stress is increased in all patients and in 52% of cases is very serious.
Antioxidant status is normal in 46% of cases and 14% show a high deﬁciency. Four
patients deserted the study for a bad compliance to the administration of PROther
not related to the product. In 6 patients we have done the ﬁrst control after three
months from the recruitment. All these cases show an improved oxidative status.
Oxidative stress has become normal in one patient. Antioxidant status has become
normal in 4 cases. All 6 patients report subjective clinical improvement. On the base
of the clinical parameters, respiratory and nutritional conditions are stable in 4 cases
and improved in 2. The quality of life test is better in all patients. Collected data
conﬁrm a high level of oxidative status in CF patients. Oral addition of whey protein
isolate with high content of cysteine seems efﬁcacious to improve the oxidative
status. Oxidative status improvement could correlate to a clinical improvement.
These observations coming from preliminary data must be conﬁrmed. We think
useful to continue the valuation of the efﬁcacy of oral addition of PROther and we
consider antioxidant therapy potentially important in CF.
P57 CYTOKINE PROFILES IN DIFFERENT MATRIXES (SERUM,
SPUTUM AND EXHALATE) OF CYSTIC FIBROSIS PATIENTS
C. Colombo1, N. Faelli1, A.S. Tirelli2, M. Conese3, D. Costantini1, A. Bifﬁ1,
V. Motta1. 1Cystic Fibrosis Centre and 2Laboratory of Clinical Pathology,
Fondazione IRCSS Policlinico Ospedale Maggiore; Mangiagalli, Regina Elena,
Milan; 3Institute for the Experimental Treatment of Cystic Fibrosis, H.S. Raffaele,
Milan, Italy
The hallmarks of cystic ﬁbrosis (CF) lung disease are bacterial infections by oppor-
tunistic pathogens and chronic inﬂammation, characterized by polymorphonucleate
neutrophils predominance, progressing to obstructive lung disease and bronchiec-
stasis.
High levels of sputum tumor necrosis factor (TNF)-a and interleukin (IL)-8 and
serum IL-6 have been found in CF patients. The aim of this study was to analyze
the major cytokines such as IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-10, interferon (IFN)-
g, the chemokines IL-8, monocyte chemoattractant protein-1 (MCP-1) and the
growth factors epidermal growth factor (EGF) and vascular endothelial growth
factor (VEGF) before and after antibiotic therapy in serum, sputum and exhalate in
order to clarify the process involved in the CF inﬂammation and to evaluate which
is the best matrix which can deﬁne this process.
We considered 10 CF patients (median age 19.5± 4, 6 M, 4 F) who were admitted at
the CF Center of the University of Milan for i.v. antibiotic therapy during acute res-
piratory exacerbation. Before and after treatment all patients underwent routine lab-
oratory determinations, sputum culture and standard spirometry. Serum, sputum and
exhalate interleukins, chemokines and growth factors were analyzed simultaneously
by means of the Evidence® biochip array (Randox) on semiautomated instrument.
Results at admission and the percentage of signiﬁcant changes after six months are
reported in the table. After treatment, chemokines and growth factors decreased
in a different manner for the considered matrix, only VEGF seemed to be always
signiﬁcantly decreased. No signiﬁcant change was found for IFN-g, IL-6 and IL-4.
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Serum Mean 5.8 4.1 34.7 378 1.5 187 3.41 8.06 0.68 2.28 367 135
SD 4.6 3.5 69.0 935 1.4 128 3.59 5.83 0.74 2.82 286 107
change (%) −26 −41 −34 −28 −56
Sputum Mean 6.9 12.2 10.5 21852 6.2 2297 1.66 153 102 1344 66 493
SD 11.0 6.1 12.4 15540 10.9 1412 5.71 239 123 1103 72 548
change (%) −78 −41 −56 73 −10
Exhalate Mean 2.1 4.6 0.2 0.4 0.6 12.2 3.43 1.79 0.43 1.24 2.47 0.60
SD 4.0 4.9 0.3 0.2 1.1 32.2 9.74 3.93 0.22 2.11 3.94 0.25
change (%) −17 −52 −75 −12 −59
In conclusion, antibiotic therapy in CF patients could be monitored by cytokine
proﬁles in sputum and serum, while exalate levels are too low to be useful. VEGF,
a growth factor involved in tissue remodeling, needs further studies.
P58* CYSTIC FIBROSIS RELATED DIABETES IS ANTICIPATED BY
REDUCED INSULIN SECRETION DURING OGTT
A. Battezzati1,2, P.M. Battezzati3, D. Costantini2, L. Zazzeron2, M.C. Russo2,
V. Dacco`2, V. Motta2, C. Colombo2. 1ICANS – DiSTAM, University of Milan,
Milano, Italy; 2CF Centre, Fondazione IRCCS Ospedale Maggiore Policlinico,
Mangiagalli, Regina Elena, University of Milan, Milano, Italy; 3Dept of Medicine,
Surgery and Dentistry, Universita` degli Studi di Milano, Milano, Italy
Diabetes in Cystic Fibrosis (CFRD) is increasingly common with advancing age
because of a combination of insulin resistance and insulin secretory defects. Many
patients are normoglycemic or even hypoglycemic after overnight fast, and there
are repeated changes of glucose tolerance status from normal to diabetes and vice-
versa, for many years and for unclear reasons. These features render difﬁcult the
prediction of CFRD development.
This study aimed to detect predictive factors of CFRD development in patients
routinely undergoing yearly Oral Glucose Tolerance Test (OGTT) evaluations.
Starting from 2002, all patients followed at the CF Center in Milan aged >10 years
and without established CFRD undergo OGTT yearly. Among those who received
their ﬁrst OGTT between 2002 and 2004, 14 had developed deﬁnitive diabetes
by April 2007. Each of them was matched with patients of same sex and age,
who underwent an OGTT in the same month and year but did not develop CFRD
(n = 20). Logistic regression, controlled for age, sex and follow-up time, was used
to identify CFRD predictors among factors including glucose, insulin and c-peptide
concentrations and area under the curve (AUC) during OGTT, insulin sensitivity
indexes (HOMA and QUICKI).
In the group that developed CFRD, baseline glucose concentration was increased
(92±6 vs 72±3mg/dl, mean±SEM, p = 0.034) whereas insulin and c-peptide
concentrations were similar (5.4±0.61 vs 7.8±1.4 mU/ml, and 1.4±0.1 vs 1.4±0.2
ng/ml). Glucose (p = 0.010) and insulin AUCs (p = 0.030) were the most important
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predictive variables, respectively directly and inversely related to CFRD develop-
ment (pseudo R2 for the model: 0.581, p< 0.001). Glycated hemoglobin and base-
line glucose concentrations were directly related with outcome at univariate analysis
whereas c-peptide concentrations were inversely related. In contrast, no relationship
emerged between insulin-sensitivity indexes and outcome. Anthropometric (weight,
height z scores, BMI) and pulmonary function indexes were also unrelated.
Conclusions: Defects in insulin secretion are determinants of subsequent CFRD
development. The evaluation of insulin concentrations during OGTT may be helpful
in CFRD prediction.
This study has been supported by a grant of Fondazione per la Ricerca sulla Fibrosi
Cistica ONLUS – Verona (Progetto FFC 16/2005).
*This Poster has been presented also as Oral Communication, by invitation of
the Scientiﬁc Committee
P59 CONTINUOUS SUBCUTANEOUS GLUCOSE MONITORING IN
CYSTIC FIBROSIS (CF) PATIENTS
F. Patriarchi, A. Menichella, F. Costantino, R. Scrocca, S. Bertasi, S. Quattrucci.
Cystic Fibrosis Center, Department of Pediatrics, “Sapienza” University of Rome,
Italy
Objectives:
1. To study the effectiveness and reliability of the continuous monitoring of blood
glucose (CGMS) in CF patients, to be able to identify at an early stage any
condition of glycemic intolerance (IGT) or even diabetes.
2. To evaluate if the pre-diabetic treatment with insulin may lead to an improvement
of CF pts glyco-metabolic control and of other clinical parameters such as BMI
and FEV1.
Materials and Methods: We evaluated 10 CF pts (5 M and 5 F) with standard
OGTT or altered baseline glycemic values. These pts had also shown a decrease in
FEV1 and BMI values during the 2 years before the beginning of the study.
A microdialysis ﬁber was inserted subcutaneously into the periumbelical region
and perfused with a buffer solution. Glucose concentrations in the dialysate were
measured every 3 minutes by the glucose sensor over a 48-h period, during which
6 capillary blood samples were also collected before and after the 3 mean meals to
evaluate the correlation between CGMS and traditional methods. The pts diagnosed
for Cystic Fibrosis Related Diabetes (CFRD) as a result of monitoring, began
insulinic therapy. After a follow-up period of 14 months glycaemia, FEV1 and
BMI were evaluated again for each of them.
Results: Both the insertion of the ﬁber and the wearing of the device were well
tolerated by the pts. Subcutaneous glucose levels were well correlated with capillary
glucose measurements (r = 0.88, P< 0.001) over a wide range (45–250mg/dl) for
up to 48 h. An analysis of 120 relevations showed a linear relationship between
the CGMS and serial capillary blood glucose levels, and 98.33% of the data fell
in the A and B regions of the error grid analysis. The results of CGMS for 48
hours conﬁrmed the presence of IGT in all pts and identiﬁed early CFRD in 6 pts
who had glycemic peaks > 200mg/dl. After they were given insulinic therapy they
showed an improvement of the glyco-metabolic control and an increasement of 6%
of BMI values during the 14 months of follow up. FEV1% values were unchanged.
Conclusions: The CGMS demonstrated high reliability and provided much more
informations about glycemic excursions and glucose trends than the traditional
diagnostic methods, making it possible to identify earlier the CFRD in CF pts and
begin as soon as possible an individual insulinic treatment.
P60 EXCEPTIONALLY EARLY OCCURRENCE OF EBV RELATED
LYMPHOMA AFTER LUNG TRANSPLANTATION
V. D’Alu`, M. Rolla, A. Menichella, F. Patriarchi, L. Locorriere, C. Scacchi,
D. Russo, P. Troiani, S. Quattrucci. Cystic Fibrosis Center, Department of
Pediatrics, “Sapienza” University of Rome, Italy
We basically describe the case of a CF pt that developed fatal EBV related
lymphoma 4 months after lung transplantation. A 17 years old female CF pt
underwent bilateral sequential lung transplantation uneventful in May 2006. All
other recipients from the same multi-organ donor are currently alive and well
with no evidence of lymphoproliferative disease. Standard immunosuppression was
instituted with Tacrolimus, Azathioprine and Prednisone. In October 2006 the pt
was readmitted to the hospital with a decrease of FEV1 of > 10%, increased
inﬂammation index, anemia, low platelets count, fever (39−40º). Chest x-ray and
CT showed diffused peribronchial inﬁltrates. Physical and abdominal examination
was negative; abdominal echography was also negative. Wide spectrum antibiotics
were administered. Bacteriology, virology and fungal exams were performed, but
all proved negative, including the search for EBV and CMV. Still, high fever
(39−40º) persisted along with lymphocytosis and neutropenia. With the suspect
of CMV infection Ganciclovir (10mg/kg/die IV) and immunoglobulins were
administered. Immunosuppression was discontinued. Ten days after admission,
without any clinical improvement, the spleen became palpable and a laterocervical
lymphonodus evident. A biopsy was immediately performed; abdominal echography
and CT were also performed. Multiple lymphadenopaties were revealed, along with
hepatosplenomegaly and moderate pleural effusion. EBV related lymphoma was
suspected on the basis of these ﬁndings and Retuximab therapy was started. The
clinical setting deteriorated over the following days and multiple organ failure
developed. The patient died on the 18th day after admission.
Necropsy conﬁrmed clinical ﬁndings, and in situ hybridization conﬁrmed the
expression of EBV genome in over 90% of the large B Lymphoma cells.
We believe it is important to be aware that Lymphoma can develop also in the early
postoperative period after lung transplantation. Although it is common knowledge
that lymphoproliferative disease can occur in as much as 10% of lung transplanted
patients, this usually occurs years after the transplant. The early occurrence of this
dramatic complication certainly entails exceptional severity and difﬁcult diagnostic
problems, which might be facilitated by its awareness.
P61 TOTIRESISTENT BURKHOLDERIA CEPACIA COMPLEX SEPSIS
IN A 62-YEAR-OLD WOMAN WITH CYSTIC FIBROSIS
A. Antonelli, I. Balteri, A. Schreiber, B. Grosso, B. Messore, V. De Rose. Centro
Regionale per la Fibrosi Cistica Piemonte e Valle d’Aosta – Settore Adulti; Clinica
di Malattie dell’Apparato Respiratorio – Universita` degli Studi di Torino; Azienda
Ospedaliera San Luigi Gonzaga, Orbassano, Torino, Italy
Colonization of cystic ﬁbrosis (CF) airways with Burkolderia cepacia complex
(Bcc) is associated with an accelerated pulmonary deterioration and increased
mortality. Bcc sepsis is one of the most dramatic events that can occur in a patient
chronically infected.
We describe the case of a 62-year-old woman with CF (diagnosed at the age of
50), with type II chronic respiratory insufﬁciency in long term oxygen therapy and
nocturnal non-invasive ventilation, severe obstructive respiratory impairment (FEV1
29% of the predicted value), totiresistant B. cenocepacia (genomovar III) chronic
pulmonary infection. On July 2007 she presented with obnubilation, worsened gen-
eral and respiratory conditions and pyrexia; blood culture detected Bcc septicaemia.
The organism was resistant to all antibiotics singly and synergically in vitro tested,
and the sepsis occurred while she was being treated with intravenous ceftazidim
and oral co-trimoxazole.
Multiple antibiotics, including levoﬂoxacin per os, ceftazidim i.v., meropenem as
continuous intravenous infusion associated with high-dose i.v. methylprednisolone
were administered.
Despite the fact that Bcc was resistant to all tested antibiotics, her clinical conditions
progressively improved and she overcame the acute Bcc sepsis.
The exact mortality rate associated with Bcc septicaemia in CF patients is not
known, but it is thought to approach 100%.
We speculate that the intensive antibacterial therapy, in particular the continuous
intravenous infusion of meropenem, and the anti-inﬂammatory effects of high-dose
corticosteroids, could signiﬁcantly contribute to the survival of the patient.
Moreover, the favourable outcome of this case highlights that the resistance to
antibiotics detected in vitro does not always correspond to clinical inefﬁcacy.
P62 FUNCTIONAL ENDOSCOPIC SINUS SURGERY (FESS) IN
PATIENTS WITH CYSTIC FIBROSIS (CF)
C. Scacchi, L. Locorriere, V. Savastano, F. Zardo, D. Russo, S. Bertasi. Cystic
Fibrosis Center, Department of Pediatrics, “Sapienza” University of Rome, Italy
Objective: To determine the effectiveness of FESS through the reduction of
symptoms and the improvement of related clinical parameters in children and young
adults with CF and sinonasal disease (SND).
Materials and methods: 12 children and young adults (15 years median age;
range 7–38) with medically refractory SND were examined before and after FESS.
The main outcome measures were sinonasal symptoms, spirometric values (forced
expiratory volume in 1 second, FEV1, and peak expiratory ﬂux, PEF), and number
of hospitalizations. The extent of polyposis was graded endoscopically and on
computer tomography images. The sinonasal symptoms were inquired through a
questionnaire pre- and postoperatively.
Results: The mean follow up time after surgery was 15.1 months. Postoperatively,
polyp recurrence was seen in 5 pts of 12. Before surgery, bilateral nasal polyposis
was an endoscopic ﬁnding in 11 pts of 12, and 50% of them had polyps occluding
the middle meatus (grade 2 polyposis). 4 pts had undergone previous polypectomy
in other centers. The symptoms complained were nasal obstruction (100%), nasal
discharge and postnasal drip (67%) and anosmy (50%). Only 2 pts complained
headache. After FESS, 4 pts reported no nasal obstruction and marked decline in
the frequency of nasal discharge and postnasal drip (25%). Headache shows no
improvement.
Spirometric values and the number of pulmonary exacerbations were found to be
related to the severity degree of lung disease. On the basis of these observations CF
